Navigation Links
Apieron, Inc. Begins Customer Shipments of the Insight(TM) eNO System
Date:5/1/2008

Insight Measures Exhaled Nitric Oxide for More Targeted Asthma Control

MENLO PARK, Calif., May 1 /PRNewswire/ -- Apieron, Inc. (http://www.apieron.com) announced today that it has begun shipments of its Insight(TM) eNO System. Cleared by the FDA in March 2008, the Insight eNO System combines the accuracy, speed, and ease-of-use needed for the healthcare professional to provide office-based measurements of exhaled nitric oxide (eNO). Exhaled nitric oxide is a well established clinical indicator of airway inflammation and asthma control. With the use of eNO measurements, physicians can adjust inhaled corticosteroid therapy to optimize asthma control and avoid exacerbations or 'asthma attacks'.

The Insight eNO System's proprietary biosensor technology accurately measures eNO in parts per billion. Its single-use breath tubes are designed to be hygienic and convenient for the patient, and the disposable sensor generates a reading in less than a minute. Patient data can be stored and maintained in a unique format for trend analysis and printed for insurers' and patients' files. All of the System's functions are accessible through a small desktop monitor with a large color display and clinician-friendly interface.

"We showcased the Insight System at the March meeting of the American Academy of Allergy, Asthma and Immunology, and physicians responded enthusiastically to its graphical interface and its elegant technology," said Rich Lotti, President and CEO of Apieron, Inc. "As current methods for monitoring asthma airway inflammation are subjective, the Insight eNO System provides quantifiable information to increase therapeutic compliance. We believe this product will enable physicians to optimize medical therapy on an individualized basis, and therefore improve the standard of care for patients with asthma."

Sales and distribution of the Insight eNO System have been initiated with the introduction of an Apieron National Direct Sales Force in targeted major metropolitan regions.

About Apieron Inc.

Apieron Inc. is a private, venture-backed medical device company based in Menlo Park, CA that was funded in 2003 to develop a simple-to-use, non- invasive monitor for the measurement of exhaled nitric oxide (eNO) for the management of asthma. The Apieron biosensor technology platform utilizes a patented technology that allows for the highly sensitive detection of selected analytes such as eNO. Apieron is committed to collaborating with physicians and patients to develop innovative medical solutions to improve quality of life and standards of care.

Refer Questions to:

Holly McGarraugh

Apieron, Inc.

650-454-8101


'/>"/>
SOURCE Apieron, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
2. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
3. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
4. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. Dynavax Begins TOLAMBA(TM) Environmental Exposure Chamber Study
9. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
10. DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
11. Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
(Date:5/24/2016)... , May 24, 2016 ... den Markt gebracht, die es Ärzten erlaubt, ihre ... zu behandeln: MDLinking kombiniert Live Streaming mit einer ... Umfeld zu kommunizieren. Mediziner in Europa, Afrika, Asien ... sich bereits für die Plattform registriert. ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... An influential ... for a third time to shed lights on the variety of topics detailing why ... stories, “Nurse Appreciation” tackles why this career has gone from being in a major ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
Breaking Medicine News(10 mins):